WFH/LinkedIn
Feb 28, 2026, 14:48
WFH Acknowledges BioMarin’s Decision to Discontinue ROCTAVIAN
World Federation of Hemophilia (WFH) shared a post on LinkedIn:
“WFH Statement: the WFH acknowledges BioMarin’s decision to discontinue ROCTAVIAN and the importance of this development for the hemophilia community.
We urge BioMarin and other gene therapy developers to continue rigorous long-term safety monitoring of all discontinued products, and to preserve and share relevant clinical data that can inform ongoing scientific understanding and support patient safety.
For the full WFH position and our emphasis on preserving data in the WFH Gene Therapy Registry, please read our complete statement here.”
Other articles about World Federation of Hemophilia on Hemostasis Today.
-
Jul 19, 2026, 05:01Maissa El-Qendouci: Optimizing Iron Deficiency Diagnosis in TAVR
-
Jul 19, 2026, 04:39Saoud Hassan: Identifying Monocytic Precursors Under the Microscope
-
Jul 19, 2026, 04:23Iris van Moort: Expert Insights on Pediatric Hemostasis Diagnostics at ISTH 2026
-
Jul 19, 2026, 04:09Er. Subodh Grewal: How Platelet Histograms Support Hematology Diagnosis
-
Jul 19, 2026, 03:53Serhii Pelishenko: Current Evidence on Kaolin and Chitosan Dressings
-
Jul 18, 2026, 23:52Chinua Onyebuchi: Applications Now Open for the European Stroke Master Programme
-
Jul 18, 2026, 22:43Exploring the Ultra-Late Window for Stroke Treatment – International Journal of Stroke
-
Jul 18, 2026, 21:38Swastik Sharma Deviprasad Bhat: A One-Minute Guide to Recognizing Stroke
-
Jul 18, 2026, 21:05Federica Fedele: From One-Size-Fits-All to Personalized Care